PMID- 26151294
OWN - NLM
STAT- MEDLINE
DCOM- 20160620
LR  - 20181202
IS  - 1521-0499 (Electronic)
IS  - 0190-2148 (Linking)
VI  - 41
IP  - 7
DP  - 2015
TI  - Edaravone protects rats and human pulmonary alveolar epithelial cells against 
      hyperoxia injury: heme oxygenase-1 and PI3K/Akt pathway may be involved.
PG  - 404-14
LID - 10.3109/01902148.2015.1054053 [doi]
AB  - PURPOSE/AIM: Hyperoxic acute lung injury (HALI) is a clinical syndrome as a 
      result of prolonged supplement of high concentrations of oxygen. As yet, no 
      specific treatment is available for HALI. The present study aims to investigate 
      the effects of edaravone on hyperoxia-induced oxidative injury and the underlying 
      mechanism. MATERIALS AND METHODS: We treated rats and human pulmonary alveolar 
      epithelial cells with hyperoxia and different concentration of edaravone, then 
      examined the effects of edaravone on cell viability, cell injury and two 
      oxidative products. The roles of heme oxygenase-1 (HO-1) and PI3K/Akt pathway 
      were explored using Western blot and corresponding inhibitors. RESULTS: The 
      results showed that edaravone reduced lung biochemical alterations induced by 
      hyperoxia and mortality of rats, dose-dependently alleviated cell mortality, cell 
      injury, and peroxidation of cellular lipid and DNA oxidative damage. It 
      upregulated cellular HO-1 expression and activity, which was reversed by PI3K/Akt 
      pathway inhibition. The administration of zinc protoporphyrin-IX, a HO-1 
      inhibitor, and LY249002, a PI3K/Akt pathway inhibitor, abolished the protective 
      effects of edaravone in cells. CONCLUSIONS: This study indicates that edaravone 
      protects rats and human pulmonary alveolar epithelial cells against 
      hyperoxia-induced injury and the antioxidant effect may be related to 
      upregulation of HO-1, which is regulated by PI3K/Akt pathway.
FAU - Cao, Huifang
AU  - Cao H
AD  - a 1 Department of Respiratory Diseases, ChangHai Hospital , Second Military 
      Medical University , Shanghai, China.
FAU - Feng, Ying
AU  - Feng Y
AD  - b 2 Department of Respiratory Diseases, Jing'an District Centre Hospital of 
      Shanghai , Huashan Hospital Fudan University, Jing'An Branch , Shanghai, China.
FAU - Ning, Yunye
AU  - Ning Y
AD  - a 1 Department of Respiratory Diseases, ChangHai Hospital , Second Military 
      Medical University , Shanghai, China.
FAU - Zhang, Zinan
AU  - Zhang Z
AD  - b 2 Department of Respiratory Diseases, Jing'an District Centre Hospital of 
      Shanghai , Huashan Hospital Fudan University, Jing'An Branch , Shanghai, China.
FAU - Li, Weihao
AU  - Li W
AD  - b 2 Department of Respiratory Diseases, Jing'an District Centre Hospital of 
      Shanghai , Huashan Hospital Fudan University, Jing'An Branch , Shanghai, China.
FAU - Li, Qiang
AU  - Li Q
AD  - a 1 Department of Respiratory Diseases, ChangHai Hospital , Second Military 
      Medical University , Shanghai, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Exp Lung Res
JT  - Experimental lung research
JID - 8004944
RN  - 0 (Antioxidants)
RN  - 0 (Protoporphyrins)
RN  - 15442-64-5 (zinc protoporphyrin)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - S798V6YJRP (Edaravone)
RN  - T3CHA1B51H (Antipyrine)
SB  - IM
MH  - Acute Lung Injury/drug therapy/metabolism
MH  - Alveolar Epithelial Cells/*drug effects/metabolism
MH  - Animals
MH  - Antioxidants/metabolism
MH  - Antipyrine/*analogs & derivatives/pharmacology
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Edaravone
MH  - Epithelial Cells/*drug effects/metabolism
MH  - Heme Oxygenase-1/*metabolism
MH  - Humans
MH  - Hyperoxia/*drug therapy/metabolism
MH  - Male
MH  - Oxidation-Reduction/drug effects
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Protoporphyrins/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Up-Regulation/drug effects
OTO - NOTNLM
OT  - HO-1
OT  - PI3K/Akt pathway
OT  - edaravone
OT  - hyperoxia
OT  - oxidative injury
EDAT- 2015/07/08 06:00
MHDA- 2016/06/21 06:00
CRDT- 2015/07/08 06:00
PHST- 2015/07/08 06:00 [entrez]
PHST- 2015/07/08 06:00 [pubmed]
PHST- 2016/06/21 06:00 [medline]
AID - 10.3109/01902148.2015.1054053 [doi]
PST - ppublish
SO  - Exp Lung Res. 2015;41(7):404-14. doi: 10.3109/01902148.2015.1054053.